scholarly journals SAT0504 STING-ASSOCIATED VASCULOPATHY WITH ONSET IN INFANCY (SAVI SYNDROME) CAN MIMIC JUVENILE IDIOPATHIC ARTHRITIS.

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1208.2-1208
Author(s):  
M. Lopez Corbeto ◽  
E. Moreno Ruzafa

Background:STING-associated vasculopathy with onset in infancy (SAVI syndrome) can mimic Juvenile Idiopathic Arthritis.Objectives:The aim of this study is to describe a detailed cohort of patients with SAVI syndrome and highlight the similarity, in some cases, of the phenotype of this disease with Juvenile Idiopathic Arthritis.Methods:3 patients diagnosed with SAVI syndrome from the institution Hospital Universitari Vall d’Hebron were recruited. Written informed parental consent was obtained for the use of clinical data and pictures reported. Demographic, clinical, analytical, lung function and previous and current treatment are described.Results:Patient 1, a 11-year-old boy, was identified to carry a de novo p.V155M mutation in TMEM173. He presented at first month of life with recurrent bronchial infection and skin vasculitis lesions in nose, cheeks and toes. Arthritis affected hands, toes and knees but no erosions were found at X-Ray. Fever was not reported. High-resolution computed tomography (HRCT) of the lungs identified a nonspecific interstitial pneumonia (NSIP) and a lung biopsy showed lymphoid hyperplasia. Elevated inflammatory markers were reported and rheumatoid factor (RF), ACPA antibodies and antinuclear antibodies (ANA) were also positive. At the age of 6 years Ruxolitinib (RX) was introduced at the initial dose of 5 mg twice daily with an improvement of skin disease and lung function. Arthritis was well controlled and RX was well tolerated.Patient 2, a 17-year-old girl, was identified to carry a de novo p.V155 mutation in TMEM173. She presented at the age of 3 with a severe polyarthritis of large and small joints. No fever, skin or respiratory symptoms were reported at the beginning of the disease. Laboratory tests were positive for RF and ACPA antibodies. She was diagnosed with Polyarticular JIA and was treated with steroids and Methotrexate without improvement. Few months later she reported dyspnoea with recurrent bronchial infections. HRCT showed NSIP and lymphoid interstitial pneumopathy was found at the lung biopsy. RX was initiated at the age of 17 years but at this time lung fibrosis was stablished. Moreover, RX was not well tolerated due to headache. She requires continuous domiciliary oxygen and has been included to lung transplant.Finally, patient 3, a 29-year-old man, was recently diagnosed with a de novo p.V155 mutation in TMEM173. He presented at the age of 7 years with symmetrical polyarticular arthritis after a bronchial infection that course with fever. No skin manifestations were objectified. Autoimmune lab test was positive for RF, ACPA, and ANA. With the diagnosis of Polyarticular JIA he received different treatments with no response. Due to recurrent bronchial infections a HRCT was performed showing an ILD at bases and follicular bronchiolitis with NSIP pattern in a lung biopsy. Functional tests were worsening without any response to different treatments. SAVI syndrome was suspected, and genetic test was performed with positive result. RX was initiated but compliance was not goodConclusion:SAVI syndrome is a rare monogenic autoinflammatory disease with few cases reported in the literature. Disease phenotype could be different in every patient, with no presence of skin vasculitic lesions or fever. Patient 2 and 3, in contrast with patient 1, had severe articular and lung manifestations with no skin involvement. Furthermore, lab tests were positive for RF and ACPA and were misdiagnosed as JIA so genetic test was performed later in the follow-up. Being aware of the distinct phenotype of the disease could help the clinicians to make a PRONTO diagnostic and reassess the patients with these presentations that not respond well to conventional treatments.References:[1]Liu Y, et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med. 2014 Aug 7;371(6):507-518.Disclosure of Interests:None declared

2021 ◽  
Vol 49 (2) ◽  
pp. 030006052199221
Author(s):  
Min Cao ◽  
Hui Li ◽  
Hou-Rong Cai

The case of a patient with cough and asthma after activity that each had a 1-month duration is reported. Chest high-resolution computed tomography (HRCT) showed visceral pleural thickening in both upper lungs (especially the right lung), which was accompanied by fibrous strips and patches near the pleura, and these were accompanied by distraction bronchiectasis. Idiopathic pleuropulmonary elastosis was confirmed by thoracoscopic lung biopsy. The patient was treated with acetylcysteine, but their asthma worsened after activity and their lung function decreased significantly after 10 months. Idiopathic pleuroparenehymal fibroelastosis is a rare new type of idiopathic interstitial pneumonia, which has no effective treatment except for lung transplantation.


2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Xiyue Zhang ◽  
Wei Li ◽  
Chunyan Li ◽  
Jie Zhang ◽  
Zhenzhong Su

Abstract Background Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease with unclear pathogenesis. IPF is considered as a risk factor for lung cancer. Compared to other lung cancers, small-cell lung cancer (SCLC) has a lower incidence, but has a more aggressive course. Patients with IPF and SCLC have a lower survival rate, more difficult treatment, and poorer prognosis. Case presentation Case 1 was of a 66-year-old man with IPF for 5 years, who was admitted to our hospital for dyspnea. Case 2 was of a 68-year-old woman, who presented with chest pains, cough, and dyspnea. Both patients had extremely poor lung function. High-resolution computed tomography and pathology revealed that both patients had IPF and SCLC. Chemotherapy comprising nedaplatin (80 mg/m2) and etoposide (100 mg for 5 days) was initiated for both patients. Antifibrotic agents were continued during the chemotherapeutic regimen. Both patients showed improvement in their condition after treatment. Conclusion The favorable outcomes in these 2 cases suggests that chemotherapy is worth considering in the management of patients having SCLC and IPF with poor lung function.


2021 ◽  
pp. 0271678X2110267
Author(s):  
Peipei Pan ◽  
Shantel Weinsheimer ◽  
Daniel Cooke ◽  
Ethan Winkler ◽  
Adib Abla ◽  
...  

Brain arteriovenous malformations (bAVM) are an important cause of intracranial hemorrhage (ICH), especially in younger patients. The pathogenesis of bAVM are largely unknown. Current understanding of bAVM etiology is based on studying genetic syndromes, animal models, and surgically resected specimens from patients. The identification of activating somatic mutations in the Kirsten rat sarcoma viral oncogene homologue (KRAS) gene and other mitogen-activated protein kinase ( MAPK) pathway genes has opened up new avenues for bAVM study, leading to a paradigm shift to search for somatic, de novo mutations in sporadic bAVMs instead of focusing on inherited genetic mutations. Through the development of new models and understanding of pathways involved in maintaining normal vascular structure and functions, promising therapeutic targets have been identified and safety and efficacy studies are underway in animal models and in patients. The goal of this paper is to provide a thorough review or current diagnostic and treatment tools, known genes and key pathways involved in bAVM pathogenesis to summarize current treatment options and potential therapeutic targets uncovered by recent discoveries.


1988 ◽  
Vol 254 (1) ◽  
pp. 67-71 ◽  
Author(s):  
B Rüstow ◽  
Y Nakagawa ◽  
H Rabe ◽  
K Waku ◽  
D Kunze

1. Phosphatidylinositol (PI) is a minor component of lung surfactant which may be able to replace the functionally important phosphatidylglycerol (PG) [Beppu, Clements & Goerke (1983) J. Appl. Physiol. 55, 496-502] without disturbing lung function. The dipalmitoyl species is one of the main species for both PI (14.4%) and PG (16.9%). Besides the C16:0--C16:0 species, the C16:0--C18:0, C16:0--C18:1, C16:0--C18:2 and C18:0--C18:1 species showed comparable proportions in the PG and PI fractions. These similarities of the species patterns and the acidic character of both phospholipids could explain why surfactant PG may be replaced by PI. 2. PI and PG were radiolabelled by incubation of microsomal fractions with [14C]glycerol 3-phosphate (Gro3P). For 11 out of 14 molecular species of PI and PG we measured comparable proportions of radioactivity. The radioactivity of these 11 species accounted together for more than 80% of the total. The addition of inositol to the incubation system decreased the incorporation in vitro of Gro3P into PG and CDP-DG (diacylglycerol) of lung microsomes (microsomal fractions), but did not change the distribution of radioactivity among the molecular species of PG. These results supported the idea that both acidic surfactant phospholipids may be synthesized de novo from a common CDP-DG pool in lung microsomes.


PEDIATRICS ◽  
1967 ◽  
Vol 40 (6) ◽  
pp. 962-974
Author(s):  
W. A. Aherne ◽  
K. W. Cross ◽  
E. N. Hey ◽  
Sheila R. Lewis

Detailed lung function studies at the age of 8 months and 1 year are reported for an infant who weighed 992 gm at birth and who developed chronic progressive pulmonary insufficiency 2 weeks after birth. The symptoms and signs were similar to those described by Wilson and Mikity in 1960. A confirmatory lung biopsy was obtained when the child was 11 months old. Dynamic lung "compliance" was very significantly reduced while a static estimate of lung compliance was within normal limits. These and other lung function findings are interpreted as indicating that uneven alveolar ventilation was the probable functional basis for all the signs and symptoms observed.


2016 ◽  
Vol 49 (2) ◽  
pp. 112-116 ◽  
Author(s):  
Pedro Paulo Teixeira e Silva Torres ◽  
Marise Amaral Rebouças Moreira ◽  
Daniela Graner Schuwartz Tannus Silva ◽  
Roberta Rodrigues Monteiro da Gama ◽  
Denis Masashi Sugita ◽  
...  

Abstract Hypersensitivity pneumonitis is a diffuse interstitial and granulomatous lung disease caused by the inhalation of any one of a number of antigens. The objective of this study was to illustrate the spectrum of abnormalities in high-resolution computed tomography and histopathological findings related to hypersensitivity pneumonitis. We retrospectively evaluated patients who had been diagnosed with hypersensitivity pneumonitis (on the basis of clinical-radiological or clinical-radiological-pathological correlations) and had undergone lung biopsy. Hypersensitivity pneumonitis is clinically divided into acute, subacute, and chronic forms; high-resolution computed tomography findings correlate with the time of exposure; and the two occasionally overlap. In the subacute form, centrilobular micronodules, ground-glass opacities, and air trapping are characteristic high-resolution computed tomography findings, whereas histopathology shows lymphocytic inflammatory infiltrates, bronchiolitis, variable degrees of organizing pneumonia, and giant cells. In the chronic form, high-resolution computed tomography shows traction bronchiectasis, honeycombing, and lung fibrosis, the last also being seen in the biopsy sample. A definitive diagnosis of hypersensitivity pneumonitis can be made only through a multidisciplinary approach, by correlating clinical findings, exposure history, high-resolution computed tomography findings, and lung biopsy findings.


Respiration ◽  
2020 ◽  
pp. 1-8
Author(s):  
Pierre-Henri Aussedat ◽  
Nader Chebib ◽  
Kais Ahmad ◽  
Jean-Charles Glerant ◽  
Gabrielle Drevet ◽  
...  

<b><i>Background:</i></b> Video-assisted surgical lung biopsy (SLB) is performed in 10–30% of cases to establish the diagnosis of idiopathic pulmonary fibrosis (IPF). <b><i>Objectives:</i></b> The aim of the study was to analyze the impact of SLB on lung function in patients eventually diagnosed with IPF. <b><i>Methods:</i></b> This is an observational, retrospective, monocentric study of all consecutive patients eventually diagnosed with IPF in multidisciplinary discussion who underwent SLB over 10 years in a specialized center. The primary end point was the variation in forced vital capacity (FVC) before and after the SLB. The secondary end points were the variations in forced expiratory volume in one second (FEV1), total lung capacity (TLC), carbon monoxide diffusion capacity (DLCO), and morbidity and mortality associated with the SLB. <b><i>Results:</i></b> In 118 patients who underwent SLB and were diagnosed with IPF, a relative decrease in FVC of 4.8% (<i>p</i> &#x3c; 0.001) was found between measurements performed before and after the procedure. The mean FVC decrease was 156 ± 386 mL in an average period of 185 days, representing an annualized decline of 363 ± 764 mL/year. A significant decrease was also observed after SLB in FEV1, TLC, and DLCO. Complications within 30 days of SLB occurred in 14.4% of patients. Two patients (1.7%) died within 30 days, where one of them had poor lung function. Survival at 1 year was significantly poorer in patients with FVC &#x3c;50% at baseline. <b><i>Conclusion:</i></b> In this uncontrolled study in patients ultimately diagnosed with IPF, SLB was followed by a significant decline in FVC, which appears to be numerically greater than the average decline in the absence of treatment in the literature. <b><i>Summary at a Glance:</i></b> This study evaluated the change in lung function in 118 consecutive patients diagnosed with idiopathic pulmonary fibrosis by surgical lung biopsy. Forced vital capacity decreased by 156 ± 386 mL in a mean of 185 days between the last measurement before and first measurement after biopsy, representing an annualized decline of 363 ± 764 mL/year.


2021 ◽  
Vol 31 (1) ◽  
pp. 88-99
Author(s):  
S. N. Avdeev

Hypersensitivity pneumonitis (HP) is an inflammatory disease of the lungs and airways that develops in response to repeated inhalation of a wide range of aerosol antigens. The clinical picture and course of HP are highly variable and depend on such factors as the nature of the antigen, the intensity and duration of exposure to the antigen, as well as on the characteristics of the patient's immune response. The annual incidence of HAP is 1.28 -1.94 cases per 100 000. Currently, the diagnosis of HP is usually based on the characteristic clinical picture, high-resolution computed tomography (HRCT) data, bronchoscopy, lung biopsy, and evidence on the antigen. HRCT plays a central role in the diagnosis of HP. The most common finding on HRCT in HP is ground-glass opacities, which can be associated with centrilobular nodules and air trapping. In some cases, the fibrotic HP signs are very similar to those of idiopathic pulmonary fibrosis (IPF), and most changes are found in the lower regions and subpleurally. Therapy for HP usually includes avoiding exposure to the antigen, considering corticosteroids (CS) and/or immunosuppressive therapy to suppress the active inflammatory/immune response, and treating comorbidities. Nintedanib therapy in patients with progressive fibrotic HP results in a slower decline of lung function compared to placebo.


Sign in / Sign up

Export Citation Format

Share Document